Lepu Medical: Injection of Recombinant Type A Botulinum Toxin Obtains Drug Clinical Trial Approval Notice

Lepu Medical announced that its subsidiary Lepu Jiantang Pharmaceutical Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its independently developed injectable recombinant type A botulinum toxin, allowing it to conduct clinical trials. This product has advantages such as low biological risk and high purity, marking the company's excellent and efficient R&D capabilities in the dermatology field, enriching the company's product layout in dermatology, and enhancing its core competitiveness in this segment. However, this research project is still in the early stages of development, and subsequent clinical trials are characterized by high uncertainty in results, significant R&D investment, and long clinical trial cycles, posing a risk of clinical trial failure for the drug